Novartis MS Drug Cuts Relapses by Up to 35%, Falls Short of Analyst Expectations Written By sheeba farhat25 Oct 2026 10:30 AM ISTLondon: Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data...
Novartis Terminates Mid-Stage Fabhalta Trial for Lupus Nephritis Written By sheeba farhat19 Oct 2026 5:34 PM ISTBengaluru: Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing...
Novartis Signs Licensing Deal Worth Up to $7.8 Billion With Abogen for mRNA Therapies Written By sheeba farhat4 Oct 2026 9:07 PM ISTNew Delhi: Chinese biotech company Abogen ‌said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis, opens new tab to...
Novartis' listed entity renamed to Evonile Pharma Limited Written By Parthika Patel3 Oct 2026 9:00 PM ISTMumbai: Novartis' listed entity renamed to Evonile Pharma Limited with effect from October 1, 2026, following approval from the Ministry of...
Novartis Drops Experimental Amyotrophic Lateral Sclerosis Drug After Mid-Stage Trial Failure Written By sheeba farhat17 Sept 2026 10:08 PM ISTBengaluru: Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage...
Former Novartis Executive Ingrid Zhang Named Legend Biotech CEO, Succeeds Ying Huang Written By sheeba farhat16 Sept 2026 6:42 PM ISTBengaluru: Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry...
Scholar Rock Wins First USFDA Approval for Isembyld to Treat Spinal Muscular Atrophy Written By sheeba farhat14 Sept 2026 8:14 PM ISTBengaluru: The U.S. Food and Drug Administration approved Scholar Rock's therapy on Friday to treat a rare genetic condition that causes muscle...
Novartis Major Shareholder Calls for Board Shake-Up After Back-to-Back Drug Trial Setbacks Written By sheeba farhat13 Sept 2026 10:30 AM ISTZurich: A major shareholder in Novartis has called for a shake-up ​of the Swiss drugmaker's board to improve ​corporate governance after its shares...
Novartis' Muscle-Wasting Drug Del-desiran Fails Late-Stage Trial Written By sheeba farhat10 Sept 2026 6:34 PM ISTZurich: Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in...
Novartis to Axe 130 Swiss Jobs, Relocate Labs, Halt Small-Scale Biologics Production Written By sheeba farhat3 Sept 2026 5:05 PM ISTZurich: Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss...
Novartis Halts 8 CAR-T Trials After 3 Patient Deaths Linked to Severe Immune Response Written By sheeba farhat2 Sept 2026 7:27 PM ISTBengaluru: Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after...
Delhi HC Upholds Injunction Against Noviets Pharma Over NOVIETS Mark, Finds Similarity With Novartis Written By Susmita Roy19 Aug 2026 11:30 PM ISTNew Delhi: The Delhi High Court has dismissed an appeal filed by Noviets Pharma and its associated entities against an interim injunction restraining...
